Compare · AVR vs EW
AVR vs EW
Side-by-side comparison of Anteris Technologies Global Corp. (AVR) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVR and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.50B, about 52.7x AVR ($938.4M).
- Over the past year, AVR is up 77.4% and EW is up 13.1% - AVR leads by 64.3 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- EW has more recent analyst coverage (25 ratings vs 6 for AVR).
- Company
- Anteris Technologies Global Corp.
- Edwards Lifesciences Corporation
- Price
- $9.57-0.83%
- $86.34+0.45%
- Market cap
- $938.4M
- $49.50B
- 1M return
- +47.00%
- +4.33%
- 1Y return
- +77.39%
- +13.12%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 7
- 7
- Recent ratings
- 6
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AVR
- Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
- Director Knight Susan Elizabeth bought $102,228 worth of shares (11,000 units at $9.29) (SEC Form 4)
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 424B5 filed by Anteris Technologies Global Corp.
- SEC Form 3 filed by new insider Knight Susan Elizabeth
- New insider Denaro Stephen claimed ownership of 23,722 shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.
- Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
- Anteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update
Latest EW
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)